- Market Capitalization, $K 93,067
- Shares Outstanding, K 24,951
- Annual Sales, $ 0 K
- Annual Income, $ -32,940 K
- 60-Month Beta 3.09
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 1.23
|Period||Period Low||Period High||Performance|
| || |
-1.34 (-27.63%)since 06/12/20
| || |
-0.43 (-10.91%)since 04/13/20
| || |
-10.13 (-74.27%)since 07/12/19
, /PRNewswire/ -- The political push for the legalization of psychedelic products is now underway. Earlier this week, an ballot measure to legalize the use of psilocybin, a naturally occurring psychedelic...
Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for YRCW, ZYNE, WKHS, VXRT, and UAL.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, NIO, AMD, NCLH, and ZYNE.
- Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set -
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba
The marijuana stocks plunged during the coronavirus sell-off. Should investors be taking a second look?
, /PRNewswire/ -- There has been a substantial growth in demand for cannabidiol (CBD) products around the globe in recent years, mainly in developed countries such as the U.S., , and the Netherlands. As...
, /PRNewswire/ -- Despite the various stigmas associated with psychedelics, there is a growing acceptance of using psychedelic drugs specifically to treat depression. Such drugs have regularly proven...